argenx to Host Myositis R&D Webinar on June 23, 2026

Rhea-AI Summary

argenx (NASDAQ:ARGX) will host a myositis-focused R&D webinar titled “R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis” on June 23, 2026 at 2:00 p.m. ET.

The event will cover disease biology, autoantibodies, the ALKIVIA clinical program, and clinical and commercial opportunities for efgartigimod, with a live webcast and one-year replay on the argenx investor website.

News Market Reaction – ARGX

+2.18%

+2.18% Session close to close

In the May 28 session, ARGX gained 2.18%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement spotlights argenx’s continued emphasis on neuromuscular and autoimmune disease inn...

Analysis

This announcement spotlights argenx’s continued emphasis on neuromuscular and autoimmune disease innovation, focusing on autoimmune myositis and FcRn leadership. The webinar will discuss disease biology, autoantibodies as key drivers, and the ALKIVIA clinical program and efgartigimod opportunity. In the context of recent label expansions, strong financial performance, and an active late-stage pipeline, this event underscores ongoing R&D transparency. Investors may watch for deeper scientific insights and how they frame future trial readouts and commercialization strategy.

Key Figures

Webinar date: June 23, 2026 Webinar time: 2:00pm ET Webinar series count: Second webinar +1 more

4 metrics

Webinar date June 23, 2026 R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis

Webinar time 2:00pm ET Scheduled start time for myositis R&D webinar

Webinar series count Second webinar Second event in argenx’s ‘mini’ pipeline spotlight series

Replay availability Approximately one year Webcast replay period on argenx investor website

Historical Context

5 past events · Latest: May 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 18	Partner pipeline update	Positive	-2.9%	MindWalk reported HYFT-enabled pipeline breadth and active Phase 1–3 programs.
May 08	FDA label expansion	Positive	+4.0%	U.S. FDA expanded VYVGART labels to all adult gMG serotypes.
May 07	Earnings and update	Positive	-2.5%	Q1 2026 showed strong sales, profit growth, and a robust catalyst pipeline.
May 06	Conference presentation	Neutral	-2.5%	Announcement of BofA health care conference presentation and webcast access.
May 06	Management changes	Neutral	-2.5%	AGM results and CEO transition to Karen Massey with board role changes.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows strong fundamental and regulatory news sometimes met with negative price reactions, while major FDA approvals have aligned with positive moves.

Recent Company History

Over recent months, argenx has reported strong financial performance, including Q1 2026 product net sales of $1.3B and significant year-over-year profit growth, alongside transformational 2025 results. The company secured a notable U.S. FDA label expansion for VYVGART and VYVGART Hytrulo to all adult gMG serotypes and completed a CEO transition to Karen Massey. Against this backdrop, the newly announced myositis R&D webinar fits into a broader pattern of active pipeline communication and neuromuscular disease focus.

Key Terms

fcrn, autoimmune myositis, autoantibodies

3 terms

fcrn medical

"“R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis”"

The neonatal Fc receptor (FCRN or FcRn) is a protein that controls how long antibodies and the blood protein albumin stay in circulation by protecting them from being broken down. For investors, therapies that block or harness FcRn can change a drug’s dosing, effectiveness and market appeal—either by lengthening beneficial antibodies for longer-lasting treatments or by reducing harmful antibodies in autoimmune disease—so progress in FcRn-targeted programs can materially affect a biotech’s commercial value.

autoimmune myositis medical

"will focus on myositis, an autoimmune rheumatic disease associated with progressive muscle"

Autoimmune myositis is a group of conditions in which the immune system mistakenly attacks and inflames skeletal muscles, causing progressive weakness, fatigue, and reduced mobility; think of the immune system acting like a security guard that targets the body’s own muscle tissue. It matters to investors because it creates a defined market for diagnostic tests, long‑term treatments and clinical trials, so disease prevalence, therapy effectiveness, safety profiles and regulatory outcomes directly affect healthcare spending and the commercial prospects of drug developers.

autoantibodies medical

"including the role of autoantibodies as key disease drivers"

Autoantibodies are proteins made by the immune system that mistakenly target a person’s own tissues, like friendly fire where soldiers attack their own team. They matter to investors because their presence influences diagnosis, disease progression, and patient safety, which can affect demand for drugs, diagnostic tests, trial outcomes, regulatory decisions, and potential liabilities in healthcare-related companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

May 28, 2026

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled “R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis” on Tuesday, June 23, 2026, at 2:00pm ET.

The second webinar in the Company’s ‘mini’ series highlighting the argenx pipeline and research and development strategy will focus on myositis, an autoimmune rheumatic disease associated with progressive muscle damage and significant patient burden. The argenx team and leading clinicians treating myositis will discuss emerging insights into disease biology, including the role of autoantibodies as key disease drivers, as well as the ALKIVIA clinical program design and the clinical and commercial opportunity for efgartigimod.

A webcast of the event can be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.

About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit  www.argenx.com  and follow us on LinkedIn, Instagram, Facebook, and YouTube.

Contacts

Media:

Colin McBean
cmcbean@argenx.com

Investors:

Alexandra Roy
aroy@argenx.com

FAQ

When is the argenx (NASDAQ:ARGX) myositis R&D webinar scheduled?

The argenx myositis R&D webinar is scheduled for June 23, 2026 at 2:00 p.m. ET. According to argenx, it is the second webinar in its mini series highlighting the pipeline and R&D strategy focused on autoimmune myositis.

How can investors access the argenx (ARGX) myositis R&D webinar webcast?

Investors can access the argenx myositis R&D webinar via live webcast on the Investors section of argenx.com. According to argenx, a replay of the event will remain available on the website for approximately one year after the presentation.

What topics will argenx cover in the June 23, 2026 myositis R&D webinar (ARGX)?

The webinar will cover autoimmune myositis biology, including the role of autoantibodies, and the ALKIVIA clinical program. According to argenx, it will also address the clinical and commercial opportunity for efgartigimod in this severe autoimmune rheumatic disease.

Who will present during argenx’s autoimmune myositis R&D webinar for ARGX shareholders?

The webinar will feature the argenx team and leading clinicians who treat autoimmune myositis. According to argenx, these experts will discuss emerging disease insights, autoantibody-driven pathology, and how the ALKIVIA clinical program and efgartigimod fit into myositis treatment opportunities.

What is the focus of argenx’s ALKIVIA clinical program discussed in the myositis webinar?

The ALKIVIA clinical program focuses on autoimmune myositis and the role of FcRn-targeting therapy efgartigimod. According to argenx, the webinar will review its clinical program design and explore potential clinical and commercial opportunities in treating progressive muscle damage and patient burden.